Header Logo

Connection

LINGEGOWDA SELANERE MANGALA to Apoptosis

Back to Details
This is a "connection" page, showing publications LINGEGOWDA SELANERE MANGALA has written about Apoptosis.
LINGEGOWDA SELANERE MANGALA
Connection Strength
0.548
Apoptosis
  1. Tissue transglutaminase: from biological glue to cell survival cues. Front Biosci. 2006 Jan 01; 11:173-85.
    View in: PubMed
    Score: 0.095
  2. A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis. J Clin Invest. 2019 12 02; 129(12):5343-5356.
    View in: PubMed
    Score: 0.062
  3. Targeting c-MYC in Platinum-Resistant Ovarian Cancer. Mol Cancer Ther. 2015 Oct; 14(10):2260-9.
    View in: PubMed
    Score: 0.046
  4. Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res. 2009 Jun 01; 15(11):3770-80.
    View in: PubMed
    Score: 0.030
  5. Tissue transglutaminase (TG2) in cancer biology. Prog Exp Tumor Res. 2005; 38:125-38.
    View in: PubMed
    Score: 0.022
  6. EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer. Int J Mol Sci. 2024 Jan 20; 25(2).
    View in: PubMed
    Score: 0.021
  7. Combination of EphA2- and Wee1-Targeted Therapies in Endometrial Cancer. Int J Mol Sci. 2023 Feb 15; 24(4).
    View in: PubMed
    Score: 0.019
  8. MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer. Gynecol Oncol. 2021 10; 163(1):181-190.
    View in: PubMed
    Score: 0.017
  9. Combined VEGFR and MAPK pathway inhibition in angiosarcoma. Sci Rep. 2021 04 30; 11(1):9362.
    View in: PubMed
    Score: 0.017
  10. The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis. Oncogene. 2021 01; 40(2):384-395.
    View in: PubMed
    Score: 0.017
  11. PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis. EBioMedicine. 2019 Feb; 40:290-304.
    View in: PubMed
    Score: 0.015
  12. Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability. Clin Cancer Res. 2018 10 15; 24(20):5072-5084.
    View in: PubMed
    Score: 0.014
  13. Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies. J Natl Cancer Inst. 2017 07 01; 109(7).
    View in: PubMed
    Score: 0.013
  14. Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4. Oncogene. 2017 02 16; 36(7):912-921.
    View in: PubMed
    Score: 0.012
  15. Reciprocal positive selection for weakness - preventing olaparib resistance by inhibiting BRCA2. Oncotarget. 2016 Apr 12; 7(15):20825-39.
    View in: PubMed
    Score: 0.012
  16. Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. Oncotarget. 2016 Mar 22; 7(12):15093-104.
    View in: PubMed
    Score: 0.012
  17. Role of Increased n-acetylaspartate Levels in Cancer. J Natl Cancer Inst. 2016 Jan 26; 108(6):djv426.
    View in: PubMed
    Score: 0.012
  18. Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy. Oncotarget. 2015 Oct 06; 6(30):29161-77.
    View in: PubMed
    Score: 0.012
  19. Notch3 pathway alterations in ovarian cancer. Cancer Res. 2014 Jun 15; 74(12):3282-93.
    View in: PubMed
    Score: 0.011
  20. Functional roles of Src and Fgr in ovarian carcinoma. Clin Cancer Res. 2011 Apr 01; 17(7):1713-21.
    View in: PubMed
    Score: 0.008
  21. EphA2 targeted chemotherapy using an antibody drug conjugate in endometrial carcinoma. Clin Cancer Res. 2010 May 01; 16(9):2562-70.
    View in: PubMed
    Score: 0.008
  22. c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clin Cancer Res. 2010 Jan 01; 16(1):184-94.
    View in: PubMed
    Score: 0.008
  23. Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer. Cancer Biol Ther. 2009 Dec; 8(23):2263-72.
    View in: PubMed
    Score: 0.008
  24. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma. Cancer Biol Ther. 2009 Aug; 8(16):1596-603.
    View in: PubMed
    Score: 0.008
  25. EphA2 immunoconjugate as molecularly targeted chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2009 Sep 02; 101(17):1193-205.
    View in: PubMed
    Score: 0.008
  26. Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther. 2009 Jun; 8(11):1027-34.
    View in: PubMed
    Score: 0.008
  27. Functional significance of VEGFR-2 on ovarian cancer cells. Int J Cancer. 2009 Mar 01; 124(5):1045-53.
    View in: PubMed
    Score: 0.007
  28. Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver. Oncogene. 2008 Dec 04; 27(57):7192-200.
    View in: PubMed
    Score: 0.007
  29. Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res. 2008 Sep 01; 14(17):5437-46.
    View in: PubMed
    Score: 0.007
  30. Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst. 2008 Jan 16; 100(2):109-20.
    View in: PubMed
    Score: 0.007
  31. Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells. Oncogene. 2006 May 18; 25(21):3049-58.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.